Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3282426 | 0.99 | PDE4B (0.60) | PDE4BPDE4DNR3C1 | |
| Bromide SCHEMBL3285815 | 0.99 | PDE4B (0.60) | PDE4BPDE4DNR3C1 | |
| Phosphoric Acid SCHEMBL3282705 | 0.98 | PDE4B (0.58) | PDE4BPDE4DNR3C1 | |
| Sulfuric Acid SCHEMBL3283939 | 0.97 | PDE4B (0.58) | PDE4BPDE4D | |
| SCHEMBL3284167 | 0.97 | PDE4B (0.58) | PDE4BPDE4D | |
| SCHEMBL3282409 | 0.96 | PDE4B (0.57) | PDE4BPDE4D | |
| SCHEMBL5173840 | 0.96 | PDE4B (0.58) | PDE4BPDE4DNR3C1 | |
| SCHEMBL4938151 | 0.96 | PDE4B (0.58) | PDE4BPDE4DNR3C1 | |
| Nitric Acid SCHEMBL3282016 | 0.96 | PDE4B (0.56) | PDE4BPDE4DNR3C1 | |
| SCHEMBL3281712 | 0.93 | PDE4B (0.59) | PDE4BPDE4DNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | claimed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | claimed |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | claimed |
| EP-1735314-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | claimed |
| EP-1448195-B1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005090352-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1735314-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1735314-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005090352-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090352-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090354-A1 | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090352-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090354-A1 | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885PDE4D 9/4885NR3C1 964/4885 |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | PDE4B, PDE4A, PDE3B | PDE4B 1/4885PDE4D 8/4885NR3C1 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.